Prevention of Euglycemic DKA in Pre-Diabetic Patients on SGLT2 Inhibitors During Acute Illness
Immediately discontinue the SGLT2 inhibitor upon hospital admission for pneumonia and do not restart it during the hospitalization. 1, 2
Immediate Actions Upon Admission
Stop the SGLT2 inhibitor immediately when the patient presents with pneumonia. The most recent multidisciplinary consensus (2025) emphasizes that SGLT2 inhibitors should be withheld during acute illness, and the 2021 Lancet guideline explicitly states: "We do not recommend the routine use of SGLT2 inhibitors in the hospital." 1, 2
Pre-diabetic patients are at particular risk because:
- They can develop euglycemic DKA even without diabetes mellitus 1, 3
- The incidence in non-diabetic patients is 1 in 15,592 versus 1 in 339 in diabetic patients, but the risk increases dramatically during acute illness 1
- Recent case series confirm euglycemic DKA occurs in non-diabetic heart failure patients on SGLT2 inhibitors, with decreased oral intake being the common precipitant 3
Key Prevention Strategies During Hospitalization
1. Maintain Adequate Hydration and Nutrition
- Ensure continuous intravenous fluid administration with glucose-containing solutions (5% dextrose) if oral intake is reduced 4, 1
- Avoid prolonged fasting periods beyond standard guidelines 1
- The pharmacologic effects of SGLT2 inhibitors persist beyond several half-lives, so these measures are critical even after discontinuation 5
2. Monitor for Early Detection
- Check beta-hydroxybutyrate levels if the patient develops unexplained symptoms (tachycardia, dyspnea, abdominal pain, nausea) 6, 4
- Measure serum ketones and arterial blood gas if metabolic acidosis is suspected, regardless of glucose levels 7, 8
- The hallmark is high anion gap metabolic acidosis with ketonemia (beta-hydroxybutyrate >3.0 mmol/L) but glucose often <14 mmol/L 1, 7
3. Address Pneumonia-Specific Risk Factors
Pneumonia creates a perfect storm for euglycemic DKA through:
- Acute illness triggering counter-regulatory hormones 7, 9
- Reduced oral intake due to respiratory symptoms 3, 9
- Dehydration from fever and tachypnea 7
- Relative insulin deficiency state 8, 3
Critical Pitfalls to Avoid
Do not assume normal glucose excludes DKA. This is the most dangerous misconception. Two cases in the evidence showed delayed diagnosis because clinicians did not suspect DKA with euglycemia 4, 9. The "D" in DKA refers to diabetes history, not necessarily hyperglycemia 1.
Do not restart the SGLT2 inhibitor during hospitalization, even if heart failure worsens. While cessation may worsen heart failure 1, the acute risk of euglycemic DKA during pneumonia outweighs this concern. Standard heart failure management should be optimized with other agents during the acute illness.
Do not rely on sodium bicarbonate alone if euglycemic DKA develops. One case showed minimal improvement with bicarbonate monotherapy 4. Treatment requires insulin infusion (added to dextrose-containing fluids), aggressive hydration, and potassium replacement 4, 7.
When to Resume SGLT2 Inhibitor
Only consider restarting after:
- Complete resolution of acute illness
- Patient tolerating full oral intake
- No metabolic acidosis
- Discharge from hospital with close outpatient follow-up
The medication should remain discontinued for at least 3-4 days after any acute illness resolves based on perioperative data showing this duration reduces risk 1, 4, 10.
Documentation and Patient Education
Document clearly in admission orders: "Hold SGLT2 inhibitor due to acute illness and euglycemic DKA risk." Educate the patient that this is a temporary measure for safety during pneumonia treatment, and the medication can be reassessed by their outpatient cardiologist after full recovery.